The research and introduction of new drugs has been slowing down in the UK and the US. At the same time, government regulations on the safety of new drugs have increased. But Fred Steward and George Wibberley argue that there is not a simple relationship between these two trends
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Steward, F., Wibberley, G. Drug innovation—what's slowing it down?. Nature 284, 118–120 (1980). https://doi.org/10.1038/284118a0
Issue Date:
DOI: https://doi.org/10.1038/284118a0
This article is cited by
-
Predictive validity in drug discovery: what it is, why it matters and how to improve it
Nature Reviews Drug Discovery (2022)
-
Defining “Innovativeness” in Drug Development: A Systematic Review
Clinical Pharmacology & Therapeutics (2013)
-
Diagnosing the decline in pharmaceutical R&D efficiency
Nature Reviews Drug Discovery (2012)
-
Negotiation and accommodation in expert medical risk assessment and regulation: An institutional analysis of the benoxaprofen case
Policy Sciences (1994)
-
An end to the search for new drugs?
Nature (1982)